IN2014CN00414A - - Google Patents
Info
- Publication number
- IN2014CN00414A IN2014CN00414A IN414CHN2014A IN2014CN00414A IN 2014CN00414 A IN2014CN00414 A IN 2014CN00414A IN 414CHN2014 A IN414CHN2014 A IN 414CHN2014A IN 2014CN00414 A IN2014CN00414 A IN 2014CN00414A
- Authority
- IN
- India
- Prior art keywords
- amino acid
- acid sequences
- polypeptides
- proteins
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161500464P | 2011-06-23 | 2011-06-23 | |
| PCT/EP2012/061304 WO2012175400A1 (en) | 2011-06-23 | 2012-06-14 | Serum albumin binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN00414A true IN2014CN00414A (en:Method) | 2015-04-03 |
Family
ID=46298413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN414CHN2014 IN2014CN00414A (en:Method) | 2011-06-23 | 2012-06-14 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9573992B2 (en:Method) |
| EP (3) | EP4218933A1 (en:Method) |
| JP (3) | JP6324887B2 (en:Method) |
| CN (2) | CN106046168A (en:Method) |
| AU (1) | AU2012271974B2 (en:Method) |
| CA (1) | CA2839779C (en:Method) |
| CY (1) | CY1122691T1 (en:Method) |
| DK (1) | DK2723771T3 (en:Method) |
| ES (1) | ES2759936T3 (en:Method) |
| HR (2) | HRP20192160T1 (en:Method) |
| HU (1) | HUE047238T2 (en:Method) |
| IN (1) | IN2014CN00414A (en:Method) |
| LT (1) | LT2723771T (en:Method) |
| PL (1) | PL2723771T3 (en:Method) |
| PT (1) | PT2723771T (en:Method) |
| SI (1) | SI2723771T1 (en:Method) |
| WO (1) | WO2012175400A1 (en:Method) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2621953B1 (en) | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
| US9573992B2 (en) * | 2011-06-23 | 2017-02-21 | Ablynx N.V. | Serum albumin binding proteins |
| SG10201605048XA (en) * | 2011-06-23 | 2016-07-28 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
| CN106046161B (zh) * | 2011-09-30 | 2019-09-13 | 埃博灵克斯股份有限公司 | 与C-Met相关的生物物质 |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| KR20250099289A (ko) | 2014-05-16 | 2025-07-01 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| RU2746738C2 (ru) | 2014-05-16 | 2021-04-20 | Аблинкс Нв | Улучшенные вариабельные домены иммуноглобулина |
| CA2948945C (en) | 2014-05-16 | 2023-08-08 | Ablynx Nv | Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| PL3233910T3 (pl) | 2014-12-19 | 2020-06-01 | Ablynx N.V. | Dimery nanociał połączone cysteiną |
| WO2016120843A1 (en) | 2015-01-29 | 2016-08-04 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
| WO2016187594A1 (en) | 2015-05-21 | 2016-11-24 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| NO2768984T3 (en:Method) | 2015-11-12 | 2018-06-09 | ||
| HUE057241T2 (hu) * | 2015-11-13 | 2022-04-28 | Ablynx Nv | Javított, szérumalbumint kötõ immunoglobulin variábilis domének |
| AU2016357460B2 (en) * | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| CR20180278A (es) | 2015-11-18 | 2018-08-24 | Merck Sharp & Dohme | Enlazadores de pd1 y/o lag3 |
| HK1254952A1 (zh) | 2015-11-18 | 2019-08-02 | Merck Sharp & Dohme Llc | Ctla4结合剂 |
| JO3740B1 (ar) | 2015-11-18 | 2021-01-31 | Merck Sharp & Dohme | روابط pd1/ctla4 |
| TN2018000180A1 (en) | 2015-11-27 | 2019-10-04 | Ablynx Nv | Polypeptides inhibiting cd40l |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| BR112018073739A2 (pt) * | 2016-05-20 | 2019-02-26 | Harpoon Therapeutics, Inc. | proteína de ligação de albumina sérica de domínio único |
| SG11201811280QA (en) | 2016-06-23 | 2019-01-30 | Ablynx Nv | Improved pharmacokinetic assays for immunoglobulin single variable domains |
| MX2019005696A (es) | 2016-11-16 | 2019-08-14 | Ablynx Nv | Polipeptidos de reclutamiento de celulas t capaces de unir cd123 y tcr alfa/beta. |
| KR102616835B1 (ko) * | 2016-12-07 | 2023-12-22 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인 |
| CN107674122A (zh) * | 2016-12-28 | 2018-02-09 | 天津天锐生物科技有限公司 | 一种识别人血清白蛋白的单域抗体 |
| IL312292A (en) * | 2017-01-17 | 2024-06-01 | Ablynx Nv | Improved serum albumin binders |
| PT3571224T (pt) * | 2017-01-17 | 2024-11-08 | Ablynx Nv | Ligantes de albumina sérica melhorados |
| EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN |
| AU2018241286B2 (en) | 2017-03-31 | 2025-03-13 | Ablynx N.V. | Improved immunogenicity assays |
| IL300964A (en) | 2017-05-12 | 2023-04-01 | Harpoon Therapeutics Inc | mesothelin binding proteins |
| DK3694529T3 (da) | 2017-10-13 | 2024-09-23 | Harpoon Therapeutics Inc | Trispecifikke proteiner og anvendelsesfremgangsmåder |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| US20200392512A1 (en) * | 2018-02-26 | 2020-12-17 | Ablynx N.V. | Nucleotide sequences encoding peptide linkers |
| AU2019271138A1 (en) | 2018-05-14 | 2021-01-07 | Harpoon Therapeutics, Inc. | Binding moiety for conditional activation of immunoglobulin molecules |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| CN110964107B (zh) * | 2018-09-30 | 2022-08-09 | 苏州康宁杰瑞生物科技有限公司 | Met结合分子、其组合和用途 |
| CN111138536B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 抗人血清白蛋白单域抗体的制备及其应用 |
| CN111138537B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 一种抗人血清白蛋白抗体片段、制备方法和应用 |
| EP3969474A1 (en) * | 2019-05-15 | 2022-03-23 | Crescendo Biologics Limited | Binding molecules |
| TW202434620A (zh) | 2019-07-31 | 2024-09-01 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| IL293561A (en) | 2019-12-06 | 2022-08-01 | Ablynx Nv | Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23 |
| JP7719775B2 (ja) | 2019-12-06 | 2025-08-06 | アブリンクス エン．ヴェー． | ＴＮＦαおよびＯＸ４０Ｌを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド |
| CN114980974A (zh) | 2019-12-09 | 2022-08-30 | 艾伯霖克斯公司 | 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽 |
| CN110988361B (zh) * | 2019-12-13 | 2020-09-18 | 山东民康生物科技有限公司 | 人血清白蛋白去除试剂盒 |
| MA58304B1 (fr) | 2020-01-08 | 2024-11-29 | argenx BV | Antagonistes du recepteur humain neonatal fc (fcrn) pour le traitement de troubles du pemphigus |
| WO2021168303A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
| JP2023519967A (ja) | 2020-03-30 | 2023-05-15 | アブリンクス・エヌ・フェー | 多価免疫グロブリン単一可変ドメインの製造及び精製のための方法 |
| TW202229338A (zh) | 2020-09-25 | 2022-08-01 | 比利時商艾伯霖克斯公司 | 包含靶向ｉｌ－１３和ｏｘ４０ｌ的免疫球蛋白單可變結構域的多肽 |
| CN112142846B (zh) * | 2020-10-10 | 2022-07-08 | 西北大学 | Aox特异性抗体组合及其制备方法和用途 |
| WO2022089435A1 (en) * | 2020-10-27 | 2022-05-05 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of gdf15 and use thereof |
| TW202239763A (zh) | 2020-12-18 | 2022-10-16 | 比利時商艾伯霖克斯公司 | 包含靶向ＩＬ－６和ＴＮＦ－α的免疫球蛋白單可變結構域的多肽 |
| CA3203141A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
| MX2023007308A (es) | 2020-12-18 | 2023-07-04 | Ablynx Nv | Polipeptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de celulas t. |
| CN117586423A (zh) * | 2021-07-14 | 2024-02-23 | 北京质肽生物医药科技有限公司 | 用于代谢病症的融合多肽 |
| CN118556077A (zh) * | 2021-11-17 | 2024-08-27 | 南京再明医药有限公司 | 一种多特异性抗体及其药物用途 |
| AU2022409733A1 (en) | 2021-12-17 | 2024-08-01 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123 |
| WO2023134742A1 (zh) * | 2022-01-14 | 2023-07-20 | 浙江道尔生物科技有限公司 | 一种三靶点抗肿瘤药物、其制备方法及其应用 |
| AR129614A1 (es) | 2022-06-14 | 2024-09-11 | Ablynx Nv | Dominios variables únicos de inmunoglobulina que se dirigen al receptor de células t |
| WO2023242362A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | Fcrn/antigen-binding molecules and methods of use |
| AU2023313033A1 (en) | 2022-07-27 | 2025-03-13 | Ablynx Nv | Polypeptides binding to a specific epitope of the neonatal fc receptor |
| WO2024084203A1 (en) | 2022-10-18 | 2024-04-25 | Isogenica Limited | Single domain antibodies binding to albumin |
| EP4640700A1 (en) | 2022-12-19 | 2025-10-29 | Harbour Biomed (Shanghai) Co., Ltd | "kappa/lambda" fab-fab series-connection multi-specific binding protein, preparation thereof, and use thereof |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| EP4648792A2 (en) | 2023-01-09 | 2025-11-19 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| CN120530125A (zh) * | 2023-01-18 | 2025-08-22 | 北京质肽生物医药科技有限公司 | 融合多肽的液体药物组合物及其使用方法 |
| TW202448926A (zh) * | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| AU2024234615A1 (en) | 2023-03-14 | 2025-08-21 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| WO2024215940A1 (en) | 2023-04-11 | 2024-10-17 | Visterra, Inc. | Apelin receptor agonists and uses thereof |
| WO2024231348A1 (en) | 2023-05-11 | 2024-11-14 | Vib Vzw | Slc4a4/nbce1 inhibitors |
| AR132699A1 (es) | 2023-05-17 | 2025-07-23 | Odyssey Therapeutics Inc | Anticuerpos de dominio único modificados |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| TW202515917A (zh) | 2023-06-29 | 2025-04-16 | 美商奧迪希治療公司 | 抗trailr2抗原結合蛋白及其用途 |
| US20250034260A1 (en) | 2023-07-05 | 2025-01-30 | Sanofi | Fcrn antagonists for treatment of igg-related diseases and disorders |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| TW202532432A (zh) | 2023-09-22 | 2025-08-16 | 比利時商艾伯霖克斯公司 | 二及多價白蛋白結合劑 |
| WO2025080751A2 (en) | 2023-10-13 | 2025-04-17 | Odyssey Therapeutics, Inc. | Anti-cdh17 antigen-binding proteins and uses thereof |
| WO2025085553A1 (en) | 2023-10-16 | 2025-04-24 | Paragon Therapeutics, Inc. | Fcrn antagonists with improved half-life and methods of use |
| WO2025099632A1 (en) | 2023-11-08 | 2025-05-15 | Sanofi | Cd25 based lysosomal degrader and uses thereof |
| WO2025106915A1 (en) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof |
| WO2025114529A1 (en) | 2023-12-01 | 2025-06-05 | Ablynx Nv | Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety |
| WO2025133166A1 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based carriers for site-specific amine conjugation |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| US12459994B2 (en) * | 2024-04-12 | 2025-11-04 | Paragon Therapeutics, Inc. | Albumin binding proteins and methods of use |
| WO2025217579A1 (en) * | 2024-04-12 | 2025-10-16 | Paragon Therapeutics, Inc. | Anti-hsa vhh antibodies and compositions thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
| ES2338791T3 (es) | 1992-08-21 | 2010-05-12 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
| EP0698097B1 (en) | 1993-04-29 | 2001-08-16 | Unilever N.V. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DE69841562D1 (de) | 1997-10-27 | 2010-04-29 | Bac Ip Bv | Multivalente antigenbindende proteine |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| FR2846667B1 (fr) | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
| EP2316852B1 (en) | 2002-11-08 | 2014-03-05 | Ablynx N.V. | Stabilized single domain antibodies |
| CN100439400C (zh) | 2003-01-10 | 2008-12-03 | 埃博灵克斯股份有限公司 | 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用 |
| ATE465181T1 (de) * | 2004-08-05 | 2010-05-15 | Genentech Inc | Humanisierte anti-cmet-antagonisten |
| EP2172484A3 (en) * | 2005-05-18 | 2010-05-19 | Ablynx N.V. | Serum albumin binding proteins |
| US7875465B2 (en) | 2005-05-31 | 2011-01-25 | Canon Kabushiki Kaisha | Target substance capturing molecule |
| US7989219B2 (en) | 2005-05-31 | 2011-08-02 | Canon Kabushiki Kaisha | Bispecific capturing molecule |
| WO2007085814A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
| MX2008012485A (es) * | 2006-03-30 | 2008-10-10 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de c-met. |
| US7741273B2 (en) | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| BRPI0715141A2 (pt) | 2006-08-03 | 2013-06-04 | Astrazeneca Ab | agente de ligaÇço alvejante, anticorpo isolado, fragmento de anticorpo isolado, molÉcula de Ácido nucleico, vetor, cÉlula hospedeira, mÉtodos para produzir um agente de ligaÇço alvejado, para produzir um anticorpo, para produzir um fragmento de anticorpo, para tratar um tumor maligno em um animal, para tratar inflamaÇço, e para inibir a interaÇço de alfabeta6 com seu ligando, e, conjugado |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| WO2008028977A2 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| EP2086998B1 (en) * | 2006-10-11 | 2011-12-07 | Ablynx N.V. | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof |
| WO2009138519A1 (en) | 2008-05-16 | 2009-11-19 | Ablynx Nv | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| BRPI0812298A2 (pt) | 2007-05-24 | 2016-05-24 | Ablynx Nv | sequência de aminoácidos direcionada contra rankl e polipeptídeos compreendendo a mesma para o tratamento de transtornos e doenças ósseas. |
| EP2014681A1 (en) * | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| EP2197491A4 (en) | 2007-09-04 | 2011-01-12 | Univ California | HIGHAFFINE ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES TO CANCER AND TO THE DETECTION OF CANCER |
| EP2201040A1 (en) | 2007-09-24 | 2010-06-30 | Vanderbilt University | Monoclonal antibodies to respiratory syncytial virus and uses thereof |
| MX2010005783A (es) | 2007-11-27 | 2010-08-10 | Ablynx Nv | Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas. |
| US8603474B2 (en) | 2008-01-29 | 2013-12-10 | Ludwig Institute For Cancer Research, Ltd. | Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy |
| AU2009254501B2 (en) | 2008-06-05 | 2014-07-31 | Ablynx N.V. | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
| EP2143735A1 (en) | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
| WO2010042815A2 (en) | 2008-10-09 | 2010-04-15 | Duke University | Vhh antibody fragments for use in the detection and treatment of cancer |
| CA2739352C (en) | 2008-10-29 | 2021-07-13 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
| PE20120514A1 (es) * | 2009-03-27 | 2012-05-14 | Glaxo Group Ltd | Fusiones y conjugados de agentes insulinotropicos o farmacos incretina con anticuerpos dab anti-albumina serica |
| EP2507262A1 (en) | 2009-11-30 | 2012-10-10 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| EA201290525A1 (ru) | 2009-12-18 | 2013-01-30 | Санофи | Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения |
| US8337845B2 (en) | 2010-03-03 | 2012-12-25 | Boehringer Ingelheim International Gmbh | A-beta binding polypeptides |
| SG183190A1 (en) | 2010-03-10 | 2012-09-27 | Genmab As | Monoclonal antibodies against c-met |
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2621953B1 (en) * | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
| US20150344568A1 (en) | 2011-06-23 | 2015-12-03 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| SG10201605048XA (en) | 2011-06-23 | 2016-07-28 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| US9573992B2 (en) * | 2011-06-23 | 2017-02-21 | Ablynx N.V. | Serum albumin binding proteins |
| MY167125A (en) | 2011-08-17 | 2018-08-13 | Glaxo Group Ltd | Modified proteins and peptides |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
-
2012
- 2012-06-14 US US14/128,719 patent/US9573992B2/en active Active
- 2012-06-14 JP JP2014516279A patent/JP6324887B2/ja active Active
- 2012-06-14 LT LT12727658T patent/LT2723771T/lt unknown
- 2012-06-14 WO PCT/EP2012/061304 patent/WO2012175400A1/en not_active Ceased
- 2012-06-14 CN CN201610392570.9A patent/CN106046168A/zh active Pending
- 2012-06-14 DK DK12727658T patent/DK2723771T3/da active
- 2012-06-14 PL PL12727658T patent/PL2723771T3/pl unknown
- 2012-06-14 EP EP23159592.7A patent/EP4218933A1/en active Pending
- 2012-06-14 IN IN414CHN2014 patent/IN2014CN00414A/en unknown
- 2012-06-14 EP EP12727658.2A patent/EP2723771B1/en active Active
- 2012-06-14 CN CN201280030647.8A patent/CN103619878B/zh active Active
- 2012-06-14 HU HUE12727658A patent/HUE047238T2/hu unknown
- 2012-06-14 EP EP18205150.8A patent/EP3466972A1/en active Pending
- 2012-06-14 ES ES12727658T patent/ES2759936T3/es active Active
- 2012-06-14 SI SI201231696T patent/SI2723771T1/sl unknown
- 2012-06-14 CA CA2839779A patent/CA2839779C/en active Active
- 2012-06-14 PT PT127276582T patent/PT2723771T/pt unknown
- 2012-06-14 AU AU2012271974A patent/AU2012271974B2/en active Active
- 2012-06-14 HR HRP20192160TT patent/HRP20192160T1/hr unknown
- 2012-06-25 HR HRP20170535TT patent/HRP20170535T4/hr unknown
-
2017
- 2017-01-03 US US15/397,313 patent/US20170210789A1/en not_active Abandoned
-
2018
- 2018-04-11 JP JP2018076201A patent/JP6843090B2/ja active Active
-
2019
- 2019-12-10 CY CY20191101299T patent/CY1122691T1/el unknown
-
2021
- 2021-02-22 JP JP2021026177A patent/JP7304375B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL2723771T3 (pl) | 2020-04-30 |
| HRP20170535T1 (hr) | 2017-06-16 |
| CN103619878B (zh) | 2016-10-26 |
| WO2012175400A1 (en) | 2012-12-27 |
| US20170210789A1 (en) | 2017-07-27 |
| ES2759936T3 (es) | 2020-05-12 |
| JP2014520129A (ja) | 2014-08-21 |
| EP2723771B1 (en) | 2019-09-11 |
| CN106046168A (zh) | 2016-10-26 |
| AU2012271974B2 (en) | 2017-01-12 |
| EP3466972A1 (en) | 2019-04-10 |
| JP2018127478A (ja) | 2018-08-16 |
| DK2723771T3 (da) | 2019-12-02 |
| CY1122691T1 (el) | 2021-03-12 |
| AU2012271974A1 (en) | 2013-12-12 |
| JP6843090B2 (ja) | 2021-03-17 |
| HUE047238T2 (hu) | 2020-04-28 |
| PT2723771T (pt) | 2019-12-11 |
| JP2021088585A (ja) | 2021-06-10 |
| HRP20192160T1 (hr) | 2020-02-21 |
| SI2723771T1 (sl) | 2019-12-31 |
| EP2723771A1 (en) | 2014-04-30 |
| LT2723771T (lt) | 2019-12-10 |
| JP7304375B2 (ja) | 2023-07-06 |
| CA2839779C (en) | 2020-10-06 |
| EP4218933A1 (en) | 2023-08-02 |
| JP6324887B2 (ja) | 2018-05-16 |
| HRP20170535T4 (hr) | 2022-08-19 |
| CA2839779A1 (en) | 2012-12-27 |
| US9573992B2 (en) | 2017-02-21 |
| US20140228546A1 (en) | 2014-08-14 |
| CN103619878A (zh) | 2014-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN00414A (en:Method) | ||
| IN2014CN00437A (en:Method) | ||
| WO2008028977A3 (en) | Serum albumin binding proteins with long half-lives | |
| PH12019500596B1 (en) | Recombinant binding proteins and their use | |
| MX2013012844A (es) | Secuencias de aminoacidos dirigidas contra il-17a, il-17f y/o il-17a/f y polipeptidos que comprenden las mismas. | |
| WO2013040093A3 (en) | Glucagon-like peptide-2 compositions and methods of making and using same | |
| PH12013500395B1 (en) | 4-1bb binding molecules | |
| CA2818990C (en) | Designed repeat proteins binding to serum albumin | |
| PH12012502272A1 (en) | Biological materials related to her3 | |
| HK1214739A1 (zh) | 工程化的分泌蛋白质和方法 | |
| MX350962B (es) | Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion. | |
| MX2015008446A (es) | Composiciones de proteinas de union multivalentes. | |
| MX2014011459A (es) | Proteinas nutritivas cargadas y metodos. | |
| IN2014DN05756A (en:Method) | ||
| WO2008043822A3 (en) | Amino acid sequences that bind to a desired molecule in a conditional manner | |
| WO2013184938A3 (en) | Fusion polypeptides comprising mucin-domain polypeptide linkers | |
| DK1888641T3 (da) | Serumalbuminbindende proteiner | |
| BR112014032316A2 (pt) | proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta | |
| HK1206764A1 (en) | Nutritive proteins and methods | |
| MX2024005945A (es) | Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos. | |
| MX366178B (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
| PH12014501200B1 (en) | Bacteriophage gene 3 protein compositions and use as amyloid binding agents | |
| HK1206763A1 (en) | Charged nutritive fragments, proteins and methods | |
| WO2014151834A3 (en) | Methods and compositions relating to anti-ccr7 antigen binding proteins | |
| MX2018005411A (es) | Polipeptidos anti il-23. |